Structure-based design, synthesis and evaluation of novel anthra[1,2-d]imidazole-6,11-dione derivatives as telomerase inhibitors and potential for cancer polypharmacology

European Journal of Medicinal Chemistry

Volumn 60, Issue , 2013, Pages 29-41

  Chen, Chun Liang ^a   Chang, Deh Ming ^a,b   Chen, Tsung Chih ^a   Lee, Chia Chung ^a   Hsieh, Hsi Hsien ^c   Huang, Fong Chun ^c   Huang, Kuo Feng ^d   Guh, Jih Hwa ^e   Lin, Jing Jer ^c,e   Huang, Hsu Shan ^a,b  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d CHI MEI MEDICAL CENTER   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Imidazole fused anthraquinones; Polypharmacology; SEAP assay; Telomerase; TRAP assay

Indexed keywords

2 (CHLOROMETHYL) 1H ANTHRA[1,2 D]IMIDAZOLE 6,11 DIONE; 2 (MORPHOLINOMETHYL) 1H ANTHRA[1,2 D]IMIDAZOLE 6,11 DIONE; 2 (THIOMORPHOLINOMETHYL) 1H ANTHRA[1,2 D]IMIDAZOLE 6,11 DIONE; 2 [(1,4 DIOXA 8 AZASPIRO[4.5]DECANE 8 YL)METHYL] 1H ANTHRA[1,2 D]IMIDAZOLE 6,11 DIONE; 2 [(3 METHOXY N METHYBENZYLAMINO)METHYL] 1H ANTHRA[1,2 D]IMIDAZOLE 6,11 DIONE; 2 [(4 METHYLPIPERAZIN 1 YL)METHYL] 1H ANTHRA[1,2 D]IMIDAZOLE 6,11 DIONE; 2 [(4 METHYLPIPERIDIN 1 YL)METHYL] 1H ANTHRA[1,2 D]IMIDAZOLE 6,11 DIONE; 2 [(AZEPAN 1 YL)METHYL] 1H ANTHRA[1,2 D]IMIDAZOLE 6,11 DIONE; 2 [(DIETHYLAMINO)METHYL] 1H ANTHRA[1,2 D]IMIDAZOLE 6,11 DIONE; 2 [(DIMETHYLAMINO)METHYL] 1H ANTHRA[1,2 D]IMIDAZOLE 6,11 DIONE; 2 [(ETHYLISOPROPYLAMINO)METHYL] 1H ANTHRA[1,2 D]IMIDAZOLE 6,11 DIONE; 2 [(ETHYLMETHYLAMINO)METHYL] 1H ANTHRA[1,2 D]IMIDAZOLE 6,11 DIONE; 2 [(METHYLPROPYLAMINO)METHYL] 1H ANTHRA[1,2 D]IMIDAZOLE 6,11 DIONE; 2 [(PIPERIDIN 1 YL)METHYL] 1H ANTHRA[1,2 D]IMIDAZOLE 6,11 DIONE; 2 [(PIPERONYLAMINO)METHYL] 1H ANTHRA[1,2 D]IMIDAZOLE 6,11 DIONE; 2 [(THIAZOLIDIN 3 YL)METHYL] 1H ANTHRA[1,2 D]IMIDAZOLE 6,11 DIONE; 2 [[(1,3 DIOXOLAN 2 YL)N METHYLMETHANAMINO]METHYL] 1H ANTHRA[1,2 D]IMIDAZOLE 6,11 DIONE; 2 [[(ANTHRACEN 10 YL)N METHYLMETHANAMINO]METHYL] 1H ANTHRA[1,2 D]IMIDAZOLE 6,11 DIONE; 2 [[2 (TRIFLUOROMETHYL)BENZYLAMINO]METHYL] 1H ANTHRA[1,2 D]IMIDAZOLE 6,11 DIONE; 2 [[3 (TRIFLUOROMETHYL)BENZYLAMINO]METHYL] 1H ANTHRA[1,2 D]IMIDAZOLE 6,11 DIONE; 2 [[4 (TRIFLUOROMETHYL)BENZYLAMINO]METHYL] 1H ANTHRA[1,2 D]IMIDAZOLE 6,11 DIONE; 2 [[4 [3 (PIPERIDIN 4 YL)PROPYL]PIPERIDIN 1 YL]METHYL] 1H ANTHRA[1,2 D]IMIDAZOLE 6,11 DIONE; 2 [[DI (2 PICOLYL)AMINO]METHYL] 1H ANTHRA[1,2 D]IMIDAZOLE 6,11 DIONE; 2 [[N METHYL 2 (PYRIDIN 2 YL)ETHANAMINO]METHYL] 1H ANTHRA[1,2 D]IMIDAZOLE 6,11 DIONE; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; IMIDAZOLE DERIVATIVE; TELOMERASE INHIBITOR; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AMINATION; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER GROWTH; CELL GROWTH; CELL VIABILITY; CRYSTALLIZATION; CYCLIZATION; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG SCREENING; DRUG SYNTHESIS; ENZYME INHIBITION; GROWTH; IC 50; IN VITRO STUDY; PHYSICAL CHEMISTRY; POLYPHARMACY; PROTEIN EXPRESSION; PROTEIN TARGETING;

ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; HUMANS; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP; TELOMERASE; TUMOR CELLS, CULTURED;

EID: 84871581139     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2012.11.032     Document Type: Article

References (33)

1. C. Monneret Recent developments in the field of antitumour anthracyclines Eur. J. Med. Chem. 36 2001 483 493
2. B. Zhang, D. Qian, H.H. Ma, R. Jin, P.X. Yang, M.Y. Cai, Y.H. Liu, Y.J. Liao, H.X. Deng, S.J. Mai, H. Zhang, Y.X. Zeng, M.C. Lin, H.F. Kung, D. Xie, and J.J. Huang Anthracyclines disrupt telomere maintenance by telomerase through inducing PinX1 ubiquitination and degradation Oncogene 31 2012 1 12
3. T.R. Cech Beginning to understand the end of the chromosome Cell 116 2004 273 279
4. K. Collins Mammalian telomeres and telomerase Curr. Opin. Cell. Biol. 12 2000 378 383
5. R.C. Allshire, M. Dempster, and N.D. Hastie Human telomeres contain at least three types of G-rich repeat distributed non-randomly Nucleic Acids Res. 17 1989 4611 4627
6. K. Collins, and J.R. Mitchell Telomerase in the human organism Oncogene 21 2002 564 579
7. B.S. Goueli, and R. Janknecht Regulation of telomerase reverse transcriptase gene activity by upstream stimulatory factor Oncogene 22 2003 8042 8047
8. R. Capper, B. Britt-Compton, M. Tankimanova, J. Rowson, B. Letsolo, S. Man, M. Haughton, and D.M. Baird The nature of telomere fusion and a definition of the critical telomere length in human cells Genes Dev. 21 2007 2495 2508
9. A. De Cian, L. Lacroix, C. Douarre, N. Temime-Smaali, C. Trentesaux, J.F. Riou, and J.L. Mergny Targeting telomeres and telomerase Biochimie 90 2008 131 155
10. S. Neidle Human telomeric G-quadruplex: the current status of telomeric G-quadruplexes as therapeutic targets in human cancer FEBS J. 277 2010 1118 1125
11. S. Zimmermann, and U.M. Martens Telomeres and telomerase as targets for cancer therapy Cell. Mol. Life Sci. 64 2007 906 921
12. R.J. O'Sullivan, and J. Karlseder Telomeres: protecting chromosomes against genome instability Nat. Rev. Mol. Cell. Biol. 11 2010 171 181
13. H.S. Huang, T.C. Chen, R.H. Chen, K.F. Huang, F.C. Huang, J.R. Jhan, C.L. Chen, C.C. Lee, Y. Lo, and J.J. Lin Synthesis, cytotoxicity and human telomerase inhibition activities of a series of 1,2-heteroannelated anthraquinones and anthra[1,2-d]imidazole-6,11-dione homologues Bioorg. Med. Chem. 17 2009 7418 7428
14. T.M. Ou, Y.J. Lu, J.H. Tan, Z.S. Huang, K.Y. Wong, and L.Q. Gu G-quadruplexes: targets in anticancer drug design ChemMedChem 3 2008 690 713
15. S. Maiti, N.K. Chaudhury, and S. Chowdhury Hoechst 33258 binds to G-quadruplex in the promoter region of human c-myc Biochem. Biophys. Res. Commun. 310 2003 505 512
16. P. Chaudhuri, B. Ganguly, and S. Bhattacharya An experimental and computational analysis on the differential role of the positional isomers of symmetric bis-2-(pyridyl)-1H-benzimidazoles as DNA binding agents J. Org. Chem. 72 2007 1912 1923
17. H.S. Huang, I.B. Chen, K.F. Huang, W.C. Lu, F.Y. Shieh, Y.Y. Huang, F.C. Huang, and J.J. Lin Synthesis and human telomerase inhibition of a series of regioisomeric disubstituted amidoanthraquinones Chem. Pharm. Bull. (Tokyo) 55 2007 284 292
18. H.S. Huang, J.F. Chiou, Y. Fong, C.C. Hou, Y.C. Lu, J.Y. Wang, J.W. Shih, Y.R. Pan, and J.J. Lin Activation of human telomerase reverse transcriptase expression by some new symmetrical bis-substituted derivatives of the anthraquinone J. Med. Chem. 46 2003 3300 3307
19. H.S. Huang, C.L. Chou, C.L. Guo, C.L. Yuan, Y.C. Lu, F.Y. Shieh, and J.J. Lin Human telomerase inhibition and cytotoxicity of regioisomeric disubstituted amidoanthraquinones and aminoanthraquinones Bioorg. Med. Chem. 13 2005 1435 1444
20. H.S. Huang, K.F. Huang, C.C. Lee, C.L. Chen, C.L. Li, and J.J. Lin NSC746364, NSC746365, and NSC746366: the spectra of cytotoxicity and molecular correlates of response to telomerase activity Anti-cancer Drugs 21 2010 169 180
21. H.S. Huang, K.F. Huang, C.L. Li, Y.Y. Huang, Y.H. Chiang, F.C. Huang, and J.J. Lin Synthesis, human telomerase inhibition and anti-proliferative studies of a series of 2,7-bis-substituted amido-anthraquinone derivatives Bioorg. Med. Chem. 16 2008 6976 6986
22. C.C. Lee, K.F. Huang, P.Y. Lin, F.C. Huang, C.L. Chen, T.C. Chen, J.H. Guh, J.J. Lin, and H.S. Huang Synthesis, antiproliferative activities and telomerase inhibition evaluation of novel asymmetrical 1,2-disubstituted amidoanthraquinone derivatives Eur. J. Med. Chem. 47 2012 323 336
23. T. Mosmann Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays J. Immunol. Methods 65 1983 55 63
24. F. Denizot, and R. Lang Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability J. Immunol. Methods 89 1986 271 277
25. P. Skehan, R. Storeng, D. Scudiero, A. Monks, J. McMahon, D. Vistica, J.T. Warren, H. Bokesch, S. Kenney, and M.R. Boyd New colorimetric cytotoxicity assay for anticancer-drug screening J. Natl. Cancer Inst. 82 1990 1107 1112
26. V. Vichai, and K. Kirtikara Sulforhodamine B colorimetric assay for cytotoxicity screening Nat. Protoc. 1 2006 1112 1116
27. D. Gomez, J.L. Mergny, and J.F. Riou Detection of telomerase inhibitors based on g-quadruplex ligands by a modified telomeric repeat amplification protocol assay Cancer Res. 62 2002 3365 3368
28. N.W. Kim, M.A. Piatyszek, K.R. Prowse, C.B. Harley, M.D. West, P.L. Ho, G.M. Coviello, W.E. Wright, S.L. Weinrich, and J.W. Shay Specific association of human telomerase activity with immortal cells and cancer Science 266 1994 2011 2015
29. B.R. Cullen, and M.H. Malim Secreted placental alkaline phosphatase as a eukaryotic reporter gene Methods Enzymol. 216 1992 362 368
30. H. Seimiya, H. Sawada, Y. Muramatsu, M. Shimizu, K. Ohko, K. Yamane, and T. Tsuruo Involvement of 14-3-3 proteins in nuclear localization of telomerase EMBO J. 19 2000 2652 2661
31. J.W. Shay, and S. Bacchetti A survey of telomerase activity in human cancer Eur. J. Cancer 33 1997 787 791
32. J.W. Shay, and W.E. Wright Telomerase therapeutics for cancer: challenges and new directions Nat. Rev. Drug Discov. 5 2006 577 584
33. B. Herbert, A.E. Pitts, S.I. Baker, S.E. Hamilton, W.E. Wright, J.W. Shay, and D.R. Corey Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death Proc. Natl. Acad. Sci. U. S. A 96 1999 14276 14281